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Abstract
Background: The development of a convenient high-throughput gene transduction approach is critical for biological
screening. Adeno-associated virus (AAV) vectors are broadly used in gene therapy studies, yet their applications in in vitro
high-throughput gene transduction are limited.
Principal Findings: We established an AAV reverse infection (RI)-based method in which cells were transduced by
quantified recombinant AAVs (rAAVs) pre-coated onto 96-well plates. The number of pre-coated rAAV particles and number
of cells loaded per well, as well as the temperature stability of the rAAVs on the plates, were evaluated. As the first
application of this method, six serotypes or hybrid serotypes of rAAVs (AAV1, AAV2, AAV5/5, AAV8, AAV25 m, AAV28 m)
were compared for their transduction efficiencies using various cell lines, including BHK21, HEK293, BEAS-2BS, HeLaS3,
Huh7, Hepa1-6, and A549. AAV2 and AAV1 displayed high transduction efficiency; thus, they were deemed to be suitable
candidate vectors for the RI-based array. We next evaluated the impact of sodium butyrate (NaB) treatment on rAAV vector-
mediated reporter gene expression and found it was significantly enhanced, suggesting that our system reflected the
biological response of target cells to specific treatments.
Conclusions/Significance: Our study provides a novel method for establishing a highly efficient gene transduction array
that may be developed into a platform for cell biological assays.
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Introduction
High-throughput gene transduction methods are needed for gene
function studies and drug discovery. Recently, reverse transfection
or reverse infection (RI) approaches have been established by
several groups [1,2,3], which appear to be promising for the large-
scale analysis of gene function. Different from conventional
transfection or infection of living cells using DNA (or RNA) or a
viral vector, reverse transfection or infection requires immobiliza-
tion of the DNA (RNA) or viral vector on a solid support.
Transduction is achieved by adding cells to the immobilized DNA
or vector, which can save time and labor and reduce readout
variation. Although encouraging, improvements are needed before
these methods are widely applied. In reverse transfection approach-
es, the transfection conditions may need to be modified when
different cell lines are used. For RI, only a lentiviral vector has been
tested [3], which may not be the best choice considering its stability.
In this report, we describe an RI protocol based on another
frequently used viral vector, an adeno-associated virus (AAV).
AAV is a 20-nm replication-defective virus that infects humans
and other primates, yet does not cause any known disease [4].
Vectors derived from AAV are attractive for gene therapy because
they transduce both dividing and non-dividing cells and have the
ability to mediate long-term transgene expression in vivo [5]. To
date, at least 11 serotypes (AAV1-11) have been described [6].
Among them, AAV1, AAV2, AAV5, and AAV8 are used more
frequently than others in gene therapy studies because of their
unique in vivo transduction profiles. AAV1 has the highest
transduction efficiency in muscle [7], AAV2 has a broad tissue
tropism, including muscle, liver, and the retina [8], AAV5 has the
highest transduction efficiency in respiratory ducts [9], and AAV8
showsstrong livertropism[10].AAVswithmosaiccapsidsrepresent
one strategy for creating new tropisms [11]. These AAV serotypes
or variants also display different transduction profiles in vitro.
As a non-enveloped icosahedron particle, AAV has distinct
characteristics, including considerable resistance to heat, organic
solvents, and pH extremes [12]. Moreover, AAV infection causes
little cellular toxicity, which is a common consequence of other
vectors [13]. It is these advantages that prompted us to attempt to
expand the in vitro applications of AAVs.
In this study, we established an AAV array in which quantified
recombinant AAVs (rAAVs) were coated on the wells of 96-well plates.
The medium was then allowed to evaporate, and the coated plates
were stored until use. Cells were then added to the prepared plates to
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13479achieve gene transduction. Our study provides a convenient high-
throughput approach to gene transduction for biological research.
Results
The AAV plasmid, genomic structure of the helper virus used
for rAAV packaging, and electron microscopic assessment.
AAV vectors harboring reporter genes were constructed by
inserting the genes encoding Gaussia luciferase (Gluc) or
enhanced green fluorescent protein (EGFP) between the
cytomegalovirus (CMV) promoter and bovine growth hormone
polyA (BGH polyA) in pAAV2neo (Fig. 1A) or pAAV5neo [14].
rAAVs were produced by infecting the AAV vector cell lines
with recombinant herpes simplex virus carrying the AAV rep
and cap genes (Fig. 1B); purification was achieved as described
previously [15]. The purified rAAV particles were somewhat
round (20–24 nm in diameter; Fig. 1C). The viral titers of the
rAAVs were measured by dot blotting, as described in the
Materials and Methods, and diluted to equal titers for coating
the plates.
Optimization of rAAV RI
To determine the optimal amount of rAAV per well, 5610
4,
5610
5,5 610
6,5 610
7, and 5610
8 viral genomes of rAAV2-Gluc
were applied to each well. After drying, 4610
4 BHK21 cells were
applied to each well. Then, 24 h later, Gluc activity was measured.
As shown in Figure 2A, Gluc activity was positively correlated with
viral load; as the viral load increased, more Gluc activity was
observed. Considering the different infectivity of AAV for different
cells, we chose to coat each well with 5610
8 viral genomes in each
of the remaining experiments.
To determine the optimal number of cells per well, various
numbers of BHK21 cells were applied to the wells coated with the
same quantity of viral genomes. Then, 48 h later, EGFP
fluorescence was assayed using an EnVision Multilabel Plate
Reader (Perkin Elmer, Waltham, MA). As shown in Figure 2B,
with the exception of AAV8, the highest level of EGFP intensity
was achieved by adding either 2.5610
4 or 1.25610
4 cells per well;
thus, 20,000–40,000 was taken as the optimal virus/cell ratio to
obtain the highest transduction efficiency. Because the highest
level of expression for most AAV serotypes was seen in the wells
with 2.5610
4 cells, we used this cell density in all subsequent
experiments.
To assess the temperature stability of the rAAV2-coated plates,
we placed the 96-well plates in incubators set at 37, 42, and 56uC
for 24 h before application of the BHK21 cells. A plate stored at
4uC was used as a control. As shown in Figure 2C, no difference in
Gluc activity was observed between the control plate stored at 4uC
and the plate incubated at 37uC. The level of Gluc activity in the
plates incubated at 42 and 56uC showed a 31–33% decrease.
However, the total level of Gluc activity was still high, suggesting
that the coated rAAVs were resistant to temperatures as high as
56uC for at least 24 h. Taken together, these data demonstrate
that rAAV-coated 96-well plates can be used for RI, and that the
rAAVs had not lost any infectivity when stored at 37uC for at least
24 h.
Transduction efficiency of the rAAVs in different cell lines
It has been reported that different rAAV serotypes displayed
different transduction efficiencies; thus, we next evaluated the
transduction efficiency of the rAAVs rAAV1, rAAV2, rAAV5/5,
and rAAV8 using multiple cell lines and the above protocol.
Hybrid vectors between AAV2 and 5 (designated rAAV25 m),
and AAV2 and AAV8 (designated rAAV28 m) were also
included in the test. The cell lines were then applied to each
viral line, as shown in Figure 3A. rAAV5/5, rAAV8, rAAV25 m,
and rAAV28 m showed low transduction efficiency in these cell
lines; conversely, rAAV1 and, especially, rAAV2 showed high
transduction efficiency in many cell lines, as assessed by
fluorescence microscopy (Fig. 3B). rAAV2 was able to infect
HEK293, BHK21, BEAS-2BS, and Huh7 cells with high
efficiency, whereas rAAV1 was able to infect HEK293,
Figure 1. The AAV plasmid, genomic structure of the helper virus used for rAAV packaging, and electron microscopic assessment.
A. Map of the AAV plasmid, showing the reporter gene; Gluc or EGFP was inserted between the CMV promoter and polyA region. B. Helper viruses
used for packaging of the rAAV with different capsids. UL2 and UL44 were both used for repcap insertion. capX and capY represent capsid genes
from the different AAV serotypes. C. Electron microscopic image of rAAV2-Gluc.
doi:10.1371/journal.pone.0013479.g001
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efficiency (Fig. 3B). Among these cell lines, BHK21 was the most
susceptible to the rAAVs (Fig. 3B). To quantify our fluorescence
microscopic observations, the level of EGFP intensity in each
plate was measured using an EnVision Multilabel Plate Reader
(Perkin Elmer). As shown in Figure 3C, the data were consistent
with those produced by fluorescence microscopy. In conclusion,
we found that rAAV2 and rAAV1 were suitable for RI as part of
a high-throughput array strategy.
Response to treatment with sodium butyrate (NaB)
We next evaluated the responses of the rAAV-transduced cell
lines to NaB, which was used as an interfering factor. NaB is
known to enhance gene expression [16]. Cells were applied to
wells coated with rAAV1 or rAAV2 in the presence or absence of
10 mM NaB. Then, 24 h later, Gluc activity in the supernatant
was measured. Gluc activity in the cells transduced by rAAV1
(Fig. 4A) or rAAV2 (Fig. 4B) was increased significantly, especially
for HEK293 and BHK21. Of rAAV2, Gluc activity in BHK21
increased from 3610
5 to 1.6610
6 relative light units (RLU;
Fig. 4B). Of rAAV1, Gluc activity in the BHK21 cells increased,
from 1.5610
5 to 4610
5 RLU (Fig. 4A). In conclusion, our data
show that our system can be used to monitor the response to a
modulating factor with substantial sensitivity.
Discussion
Current in vitro gene transfer approaches, based on liposomes
and cationic polymers, are both efficient and convenient.
However, they sometimes show relatively low reproducibility
due to various factors in the transfection procedure. To reduce
readout variation, the order of addition of DNA and adherent
cells has been reversed relative to conventional transfection
methods (i.e., the DNA is printed on a glass slide before addition
of the adherent cells). The advantages of reverse transfection [17]
procedures, compared with conventional transfection methods,
include reduced labor, the use of fewer materials, and the ability
to perform high-throughput screening. However, the efficiency of
reverse transfection varies depending on the cell type being used,
and this, in turn, limits its use in high-throughput screening. The
retroviral microarray-based platform created by Carbone et al.
[3] showed an enabling tool for functional genomics and drug
discovery. In the present study, we developed a novel gene
transduction approach by pre-coating rAAVs on a cell culture
plate and allowing them to dry until use. Our data show that the
rAAVs were resistant to temperature changes. Furthermore,
rAAVs coated on plates have been stored at 4uC for more than
half a year without an apparent loss of infectivity (data not
shown).
Figure 2. Optimization of rAAV RI. A. Transduction efficiency of different quantities of rAAV2-Gluc using 4610
4 BHK21 cells; the transduction
efficiency is represented by Gluc activity. B. Optimization of the virus/cell ratio. Different numbers of BHK21 cells were applied to a 96-well plate pre-
coated with 5610
8 viral genomes/well. The transduction efficiency is represented by the EGFP intensity. C. Temperature stability assessment of
rAAV2-Gluc. In total, 5610
8 viral genomes of rAAV were applied to each well. The plates were then treated at 4, 37, 42, or 56uC for 24 h, followed by
the application of 4610
4 BHK21 cells per well. Gluc activity was measured 24 h later.
doi:10.1371/journal.pone.0013479.g002
AAV RI Array
PLoS ONE | www.plosone.org 3 October 2010 | Volume 5 | Issue 10 | e13479AAV vectors have been broadly used in gene therapy studies,
yet their application to in vitro high-throughput transduction is
limited. In the present study, the transduction efficiency of
different rAAV serotypes or variants was evaluated in HEK293,
BHK21, BEAS-2BS, HelaS3, Huh7, Hepa1-6, and A549 cells.
Among the AAV vectors tested, rAAV1 and rAAV2 displayed the
most promising results when used for RI.
To our knowledge, this is the first report describing the RI of
AAV vectors. The data in the present study suggest that our AAV
RI method can be used to create ‘‘infection-ready’’ AAV arrays for
high-throughput biological assays. This type of array can be used
to test the response of cells to certain interfering factors, as
exemplified in this study. RNAi screening can also be achieved if
an AAV-based shRNA library is applied to the array. Additionally,
microRNA profiles of cell lines can be established if microRNA
target sequences linked with reporter genes are applied; this may
become an alternative and supplemental tool for microarray
analysis.
Materials and Methods
Cell culture
BHK21, HEK293, BEAS-2BS, HeLaS3, Huh7, Hepa1-6, and
A549 cells were maintained as monolayer cultures in Dulbecco’s
Modified Eagle’s Medium (DMEM) containing 10% fetal calf
serum, 100 mg/mL penicillin, and 100 U/mL streptomycin, as
recommended by the manufacturer (GIBCO, Gaithersburg,
MD).
Plasmid construction
pAAV2neo was constructed by inserting a fragment containing
two inverted terminal repeats (ITRs) from AAV2, the CMV
promoter, multi-cloning sites, and BGH polyA into pSV2neo [18].
pAAV2neo-Gluc and pAAV2neo-EGFP were constructed by
inserting the genes encoding Gluc and EGFP between the CMV
promoter and BGH polyA. pAAV5neo has a similar structure to
pAAV2neo, except that it carries ITRs from AAV5 rather than
from AAV2. pAAV5neo-EGFP was constructed by inserting EGFP
between the CMV promoter and BGH polyA in pAAV5neo.
rAAV vector cell lines
rAAV vector cell lines were obtained by transfecting pAAV2-
neo-Gluc, pAAV2neo-EGFP, or pAAV5neo-EGFP [14] into
BHK21 cells, which were then cultured in the presence of
800 mg/mL G418 for 2 weeks.
Preparation of competent helper virus
Recombinant herpes simplex virus type 1 carrying the AAV rep
and cap genes (HSV1-RC) was used to provide helper functions for
AAV vector packaging. rHSV1-UL2/rep2cap1, rHSV1-UL2/rep2-
cap2, and rHSV1-UL2/rep2cap8 were used to package the rAAV1,
rAAV2, and rAAV8 (containing the ITR of serotype 2 and
corresponding capsid of serotypes 1, 2, and 8) vectors, respectively;
rHSV1-UL2/rep5cap5 was used for rAAV5/5 (containing the ITR
of serotype 5 and capsid of serotype 5). rHSV1-UL2/rep2cap2-
UL44/rep5cap5 and rHSV1-UL2/rep2cap2-UL44/rep2cap8 were
Figure 3. Description of the rAAV RI-based array plate. A. Schematic view of the AAV-based RI array plate. Six types of rAAVs were applied to
96-well plates in two columns, allowing seven types of cells (and a control) to be applied simultaneously to the assay plate. B. Fluorescence
microscopic assessment of the infectivity of the rAAVs. C. EGFP intensity summary of Figure 2B.
doi:10.1371/journal.pone.0013479.g003
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capsid of serotypes 2 and 5) and rAAV28 m (containing the ITR of
serotype 2 and mosaic capsid of serotypes 2 and 8), respectively.
rAAV production
rAAVs were produced by infecting the AAV vector cell lines
with HSV1-RC at an MOI of 1–5. After 48–72 h, the infected
cells were harvested and purified, as described previously [15,19].
The rAAV titer was determined by dot blotting using a digoxin-
labeled CMV promoter fragment as the probe.
Transmission electron microscopy
Purified rAAVs were observed by transmission electron
microscopy (TECNAI 12, FEI, Blackwood, NJ) with an acceler-
ation voltage of 80 kV, as reported by Chen et al. [20].
Preparation of the rAAV-coated plates
To prepare rAAV-coated plates, 20 mL/well of rAAVs with
defined titers were added to a 96-well plate and placed under
airflow overnight in a tissue culture hood to evaporate all liquid.
The plate was stored at 4uC until use.
RI protocol
Cells were digested with 0.25% trypsin (Invitrogen, Carlsbad,
CA) to create a single-cell suspension. An equal volume of the
suspension (200 mL/well) was applied to the rAAV-coated plates
and cultured at 37uC in an incubator under 5% CO2 for 24–
48 h.
Gluc activity assay
The Gluc activity level was measured as described in the Gaussia
luciferase assay kit (New England Biolabs, Ipswich, MA) by adding
50 mLofsubstrate solutionto20 mLofthe supernatantorcelllysate,
followed by determination of the RLU using a luminometer.
Analysis of EGFP expression
EGFP expression was assayed by fluorescence microscopy
(Olympus DP70, BH2-RFL-T3). The EGFP intensities in the 96-
well plates were measured using an EnVision Multilabel Plate
Reader (Perkin Elmer).
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